Company Description
Sanara MedTech Inc., a medical technology company, develops, markets, and distributes surgical, wound, and skincare products and services to physicians, hospitals, clinics, and post-acute care settings in the United States.
The company offers CellerateRX Surgical, a medical hydrolysate of Type I bovine collagen indicated for the management of surgical, traumatic, and partial- and full-thickness wounds, as well as first- and second-degree burns.
It also develops BIASURGE, a no-rinse surgical solution used for wound irrigation; FORTIFY TRG, a freeze-dried, multi-layer small intestinal submucosa extracellular matrix sheet; FORTIFY FLOWABLE extracellular matrix, an advanced wound care device; and TEXAGEN, a multi-layer amniotic membrane allograft used as an anatomical barrier with robust handling that can be sutured for securement.
The company has a license agreement with Rochal to develop, market, and sell antimicrobial products that include BIASURGE Advanced Surgical Solution, BIAKŌS Antimicrobial Wound Gel, and BIAKŌS Antimicrobial Skin and Wound Cleanser for the prevention and treatment of microbes on the human body.
Sanara MedTech Inc. was incorporated in 2001 and is based in Fort Worth, Texas.
| Country | United States |
| Founded | 1982 |
| Industry | Medical Instruments & Supplies |
| Sector | Healthcare |
| Employees | 141 |
| CEO | Ronald Nixon |
Contact Details
Address: 1200 Summit Avenue, Suite 414 Fort Worth, Texas 76102 United States | |
| Phone | 817 529 2300 |
| Website | sanaramedtech.com |
Stock Details
| Ticker Symbol | SMTI |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0000714256 |
| CUSIP Number | 79957L100 |
| ISIN Number | US79957L1008 |
| Employer ID | 59-2220004 |
| SIC Code | 3842 |
Key Executives
| Name | Position |
|---|---|
| Ronald T. Nixon | Executive Chairman and Chief Executive Officer |
| Jacob A. Waldrop | Chief Operating Officer |
| Michael D. McNeil | Chief Accounting and Administrative Officer and Corporate Secretary |
| Elizabeth B. Taylor | Chief Financial Officer |
| Bill Fitzgerald | Chief Compliance Officer |
| Tricia Matteson | Vice President of Marketing |
| Tyler Palmer | Chief Corporate Development and Strategy Officer |
| Dr. Christopher A. Morrison FACHM, FAPWCA, FCCWS, M.D. | President of Telehealth Services |
| Dr. Rebecca Erin Mcmahon | President of Research and Development |
| Seth Yon | President of Commercial |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| May 28, 2025 | 8-K | Current Report |
| May 23, 2025 | 8-K | Current Report |
| May 14, 2025 | 10-Q | Quarterly Report |
| May 14, 2025 | 8-K | Current Report |
| Apr 22, 2025 | 8-K | Current Report |
| Apr 21, 2025 | ARS | Filing |
| Apr 21, 2025 | DEF 14A | Other definitive proxy statements |
| Apr 4, 2025 | 8-K | Current Report |
| Mar 25, 2025 | 10-K | Annual Report |
| Mar 25, 2025 | 8-K | Current Report |